Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aprea Therapeutics, Inc. - Common Stock (NQ:APRE)

0.6901 +0.0901 (+15.02%)
Streaming Delayed Price Updated: 12:48 PM EST, Feb 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Aprea Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Aprea Therapeutics Announces Additional Positive Clinical Activity for WEE1 Inhibitor, APR-1051, Including Second Partial Response in Ongoing ACESOT-1051 Trial
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Aprea Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Aprea Therapeutics Strengthens Global Patent Portfolio in DNA Damage Response (DDR) Cancer Therapeutics, Paving Way for Pipeline Growth
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Aprea Therapeutics Appoints Industry Veteran Eugene Kennedy, MD, as Chief Medical Advisor
Seasoned oncology drug development leader joins following early clinical proof-of-concept for WEE1 inhibitor, APR-1051 
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Aprea Therapeutics Announces Early Clinical Proof-Of-Concept in the Ongoing ACESOT-1051 Dose-Escalation Trial Evaluating WEE1 Inhibitor APR-1051, Including Partial Response Observed on First Scan
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Aprea Therapeutics Announces $5.6 Million Private Placement Priced At-The-Market Under Nasdaq Rules
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Aprea Therapeutics CEO Issues Letter to Shareholders Highlighting Pipeline Progress in 2025 and Outlook for 2026
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Game-Changing News: BEAT, APRE, TOON, MNTS, PRSO, PNPNF, SIGL – Stocks Under $1 Look Now
Via AB Newswire
News headline image
Aprea Therapeutics Announces $3.1 Million Private Placement Priced At-The-Market Under Nasdaq Rules
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Datavault AI (NASDAQ: DVLT) a Promising FY26 Forward Multiple, Reports +148% Q3, Expands Tokenization Globally – More Similar Stocks Inside.
Via AB Newswire
Topics Artificial Intelligence Intellectual Property
News headline image
Aprea Therapeutics (Nasdaq: APRE) Advances Cancer Pipeline as Maxim Group Sets $10 Price Target
Via AB Newswire
News headline image
Signal Advance (OTC: SIGL) CEO on The Street Podcast – Unveiling Physics-Based Encryption Built for the AI and Quantum Computing Era
Via AB Newswire
Topics Artificial Intelligence Intellectual Property
News headline image
Aprea Therapeutics Reports Third quarter 2025 Financial Results and Provides a Clinical Update
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Aprea Therapeutics (Nasdaq: APRE) Transforms Cutting-Edge Science into Next-Generation Cancer Therapies – More Stocks Inside
Via AB Newswire
Topics Artificial Intelligence
News headline image
Aprea Therapeutics Provides Clinical Update from ACESOT-1051 Trial Showing Early Signals of Activity for WEE1 Kinase Inhibitor APR-1051
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Mag 7 Undercard Stocks: PRSO, MIRA, WHWK, RDZN Surge on AI, Biotech, and Technology News – Full List Inside
Via AB Newswire
Topics Artificial Intelligence Intellectual Property
News headline image
Aprea Therapeutics Establishes Recommended Phase 2 Dose (RP2D) for ATRN-119, Considering Combination Therapies
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Aprea Therapeutics to Present at H.C. Wainwright Global Investment Conference
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Aprea Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Clinical Update
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Aprea Reports Anti-Proliferative Results and Promising Early-Stage Clinical Data for Next-Generation WEE1 Inhibitor, APR-1051, in HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Collaboration with MD Anderson Cancer Center
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Aprea Therapeutics Announces Dosing of Patient with HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Ongoing ACESOT-1051 Trial
ACESOT-1051 Trial Expanded to Include HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) Patients, Targeting Populations Most Likely to Benefit for WEEI Inhibition 
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Aprea Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Aprea Therapeutics Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for Head and Neck Squamous Cell Carcinoma (HNSCC)
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Aprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Aprea Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Aprea Therapeutics Presents Preliminary Findings on Oral WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Aprea Therapeutics to Present at Maxim 2024 Healthcare Virtual Summit
From Aprea Therapeutics
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.